missing translation for 'onlineSavingsMsg'
Få mere at vide
Få mere at vide
3-Ethyl 5-Methyl 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Fumarate, Mikromol™
Beskrivelse
3-Ethyl 5-Methyl 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Fumarate
Tekniske data
Tekniske data
| Kemisk navn eller materiale | 3-Ethyl 5-Methyl 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Fumarate |
| CAS | 2138811-33-1 |
| Analyt- eller komponentnavne | 3-Ethyl 5-Methyl 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Fumarate |
| Forsendelsestilstand | Room Temperature |
| Molekylær formel | C20 H23 Cl N2 O5 . C4 H4 O4 |
| Certificeringer/compliance | ISO 17025 |
| Synonym | Amlodipine Besilate Imp. D (EP), Amlodipine Imp. D (EP), Amlodipine USP Related Compound A, Amlodipine USP RC A, Imp. D (EP) as Fumarate: 3-Ethyl 5-Methyl 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Fumarate, 3-Ethyl 5-methyl [2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-3,5-pyridinedicarboxylate] fumarate, Amlodipine Related Compound A as Fumarate, Amlodipine Besilate Impurity D as Fumarate, Amlodipine Impurity D as Fumarate |
| InChI formel | InChI=1S/C47H53ClN3O3.BrH/c1-49(2)43(52)46(38-17-9-5-10-18-38,39-19-11-6-12-20-39)31-35-51(33-29-45(54,30-34-51)37-25-27-42(48)28-26-37)36-32-47(44(53)50(3)4,40-21-13-7-14-22-40)41-23-15-8-16-24-41;/h5-28,54H,29-36H2,1-4H3;1H/q+1;/p-5 |
| SMIL | CCOC(=O)c1c(COCCN)nc(C)c(C(=O)OC)c1c2ccccc2Cl.OC(=O)\C=C\C(=O)O |
| IUPAC navn | (E)-but-2-enedioic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate |
| Vis mere |
Produkttitel
Ved at klikke på Send, anerkender du, at du kan blive kontaktet af Fisher Scientific med hensyn til den feedback, du har givet i denne formular. Vi deler ikke dine oplysninger til andre formål. Alle angivne kontaktoplysninger skal også vedligeholdes i overensstemmelse med vores Privatlivspolitik.
Ser du en mulighed for forbedring?